Actively Recruiting
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
Led by M.D. Anderson Cancer Center · Updated on 2025-12-22
150
Participants Needed
1
Research Sites
1202 weeks
Total Duration
On this page
Sponsors
M
M.D. Anderson Cancer Center
Lead Sponsor
N
National Cancer Institute (NCI)
Collaborating Sponsor
AI-Summary
What this Trial Is About
This phase II trial studies the side effects and how well cladribine and rituximab work in treating patients with hairy cell leukemia. Drugs used in chemotherapy, such as cladribine, work in different ways to stop the growth of cancer cells either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as rituximab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cladribine together with rituximab may kill more cancer cells.
CONDITIONS
Official Title
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years and older
- Diagnosis of hairy cell leukemia established by bone marrow examination
- Patients with relapsed disease allowed if they have had no more than one prior therapy
- Women of child-bearing potential must use birth control during the study
- Performance status of 3 or less
- Creatinine level less than or equal to 2.0 unless related to the disease
- Bilirubin level less than or equal to 3.0
- Transaminases less than or equal to 3 times the upper limit of normal unless related to the disease
- No prior investigational agent use within 4 weeks before starting therapy
You will not qualify if you...
- Unable or unwilling to sign the consent form
- Known infection with HIV, hepatitis B, or hepatitis C
- Presence of active infection
- Presence of central nervous system metastases
- New York Heart Association class III or IV heart disease
- Prior chemotherapy within the last 4 weeks
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
M D Anderson Cancer Center
Houston, Texas, United States, 77030
Actively Recruiting
Research Team
F
Farhad Ravandi-Kashani
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here